{
    "clinical_study": {
        "@rank": "85555", 
        "arm_group": [
            {
                "arm_group_label": "without cirrhosis", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "with cirrhosis", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This Phase II, open-label, parallel-arm study will evaluate the safety, tolerability,\n      pharmacokinetics and antiviral activity of ritonavir-boosted danoprevir in combination with\n      Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) in treatment-na\u00efve patients of Asian\n      origin with chronic hepatitis C genotype 1. Patients will receive danoprevir 125 mg plus\n      ritonavir 100 mg as fixed dose tablet orally twice daily in combination with weekly Pegasys\n      180 mcg subcutaneously and Copegus 1000-1200 mg orally daily in divided doses. Treatment\n      duration is 12 weeks in patients without cirrhosis and 24 weeks in patients with compensated\n      cirrhosis."
        }, 
        "brief_title": "A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Fibrosis", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients of East Asian or Southeast Asian origin, >/= 18 years of age\n\n          -  Presence of chronic genotype 1 hepatitis C infection\n\n          -  Treatment-na\u00efve\n\n        Exclusion Criteria:\n\n          -  History or presence of decompensated liver disease\n\n          -  Presence or history of non-hepatitis C chronic liver disease\n\n          -  Positive for hepatitis B or HIV infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "61", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01749150", 
            "org_study_id": "YV28218"
        }, 
        "intervention": [
            {
                "arm_group_label": "without cirrhosis", 
                "description": "125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 12 weeks", 
                "intervention_name": "danoprevir + ritonavir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "with cirrhosis", 
                "description": "125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 24 weeks", 
                "intervention_name": "danoprevir + ritonavir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "without cirrhosis", 
                "description": "180 mcg sc weekly, 12 weeks", 
                "intervention_name": "peginterferon alfa-2a [Pegasys]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "with cirrhosis", 
                "description": "180 mcg sc weekly, 24 weeks", 
                "intervention_name": "peginterferon alfa-2a [Pegasys]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "without cirrhosis", 
                "description": "1000-1200 mg orally daily in divided doses, 12 weeks", 
                "intervention_name": "ribavirin [Copegus]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "with cirrhosis", 
                "description": "1000-1200 mg orally daily in divided doses, 24 weeks", 
                "intervention_name": "ribavirin [Copegus]", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ribavirin", 
                "Ritonavir", 
                "Peginterferon alfa-2a", 
                "Interferon-alpha", 
                "Lactams"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of", 
                        "zip": "614-735"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "135-710"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "120-752"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "110-744"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiayi County", 
                        "country": "Taiwan", 
                        "zip": "61363"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kaohsiung", 
                        "country": "Taiwan", 
                        "zip": "807"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taichung", 
                        "country": "Taiwan", 
                        "zip": "40447"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "100"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taoyuan", 
                        "country": "Taiwan", 
                        "zip": "333"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yunlin County", 
                        "country": "Taiwan", 
                        "zip": "640"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10700"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10330"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiang Mai", 
                        "country": "Thailand", 
                        "zip": "50200"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Korea, Republic of", 
                "Taiwan", 
                "Thailand"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTIVIRAL ACTIVITY OF RITONAVIR-BOOSTED DANOPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A PLUS RIBAVIRIN IN TREATMENT-NA\u00cfVE PATIENTS OF ASIAN ORIGIN WHO HAVE CHRONIC HEPATITIS C GENOTYPE 1 WITH OR WITHOUT COMPENSATED CIRRHOSIS", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Taiwan: TFDA"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 1.5 years"
            }, 
            {
                "measure": "Pharmacokinetics: Area under the concentration-time curve (AUC) for danoprevir/ritonavir", 
                "safety_issue": "No", 
                "time_frame": "up to 14 days"
            }, 
            {
                "measure": "Antiviral activity: Change in HCV RNA levels, measured using Roche COBAS TaqMan HCV Test v2.0 for High Pure System", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 36/48"
            }, 
            {
                "measure": "Antiviral activity: Proportion of patients with unquantifiable/undetectable HCV RNA during the study", 
                "safety_issue": "No", 
                "time_frame": "approximately 1.5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01749150"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of viral resistance to danoprevir", 
                "safety_issue": "No", 
                "time_frame": "approximately 1.5 years"
            }, 
            {
                "measure": "Rapid virological response (RVR): Proportion of patients with undetectable HCV RNA at Week 4", 
                "safety_issue": "No", 
                "time_frame": "approximately 1.5 years"
            }, 
            {
                "measure": "Complete early virological response (cEVR): Proportion of patients with undetectable HCV RNA at Week 12", 
                "safety_issue": "No", 
                "time_frame": "approximately 1.5 years"
            }, 
            {
                "measure": "Sustained virological response 12 weeks after end of treatment (SVR-12), defined as unquantifiable HCV RNA 8-20 weeks after the last day of study drug administration", 
                "safety_issue": "No", 
                "time_frame": "approximately 1.5 years"
            }, 
            {
                "measure": "Sustained virological response 24 weeks after end of treatment (SVR-24), defined as unquantifiable HCV RNA > 20 weeks after the last day of study drug administration", 
                "safety_issue": "No", 
                "time_frame": "approximately 1.5 years"
            }, 
            {
                "measure": "SVR measured as HCV RNA log10 IU/mL change from baseline to Week 12", 
                "safety_issue": "No", 
                "time_frame": "approximately 1.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}